Pharma | 24 August 2021
Lonza to build drug product manufacturing line in China
The installation is expected to be completed in 2022 and will create more than 150 new positions at the Guangzhou (CN) site
The installation is expected to be completed in 2022 and will create more than 150 new positions at the Guangzhou (CN) site
The acquisition of Vividion strengthens Bayer’s small molecule capabilities and expands Bayer’s reach into new modalities
It posted net profit of Rs.147.76 crores for the period ended June 30, 2020.
The company posted net profit of Rs.2.43 crores for the period ended June 30, 2020.
The group now has 320 approvals and has so far filed over 400 ANDAs
It posted net loss of Rs.(2429.81) crores for the period ended June 30, 2020.
The company posted net profit of Rs.89.20 crores for the period ended June 30, 2020.
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
The company posted net profit of Rs.9.06 crores for the period ended June 30, 2020.
The company posted net profit of Rs.16.18 crores for the period ended June 30, 2020.
The company posted net profit of Rs.124.45 crores for the period ended June 30, 2020.
The company posted net profit f Rs.85.45 crores for the period ended June 30, 2020.
The company posted net profit of Rs.111.44 crores for the period ended June 30, 2020.
The company reported total income Rs.18.57 crores during the period ended June 30, 2020.
The company posted net profit of Rs.321 crores for the period ended June 30, 2020.
The company posted net profit of Rs.594.6 crores for the period ended June 30, 2020.
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
The contribution of Wockhardt at Wrexham is one of the best examples of the success and significant potential of India-UK partnerships in the healthcare sector
The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval
The Cephalosporin Injectables plant has a total capacity of 26.4 million vials per year while Ethiopia is having a demand for 16 million vials
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)
_256_275.jpg)
